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1. Introduction 
The current negotiations of the Transatlantic Trade and Investment Partnership Agreement have 
been welcome by many as another opportunity to boost economic growth on both sides of the 
Atlantic, by abolishing barriers to trade, enhancing regulatory convergence and fostering mutual 
trade flows.  Others however have been far more sceptical: in the United Kingdom the debate has 
been particularly fierce and polarised, as the TTIP has increasingly been regarded as a factor 
potentially accelerating the process of ‘privatisation by stealth’ of the systems for the provision of 
state funded health care in the Member States.  In the United Kingdom, the English NHS has already 
been opened up to significant private enterprise input with the 2012 Health and Social Care Act 
which has meant, among other outcomes, the applicability of competition principles to service 
provision and has conferred to Monitor, as sector regulator, competition enforcement powers.  In 
Scotland, by contrast, the direction of travel has been substantially different, with the Parliament in 
Edinburgh being strongly committed to keeping health care provision ‘free at the point of need’ in 
the hands of the state. 
                But are these concerns justified? Or are there sufficiently strong safeguards, either in the 
Agreement itself or in the EU acquis, that will allow the UK, just as the other EU member states, to 
preserve the rich heritage of public health provision, and especially its continuity and reliability ‘free 
at the point of need’ in the face of an increasingly globalised world?  This paper aims to consider 
these questions.  After considering the scope and the limits of the EU mandate to negotiate TTIP it 
will investigate the role and the powers that the EU enjoys as an international actor, both generally 
and in the field of common commercial policy.  In that context, it will be argued that although this is 
an area which falls within the exclusive powers of the Union, the exercise of powers in this field can 
only occur consistently with the overarching principles governing the EU action, namely the principle 
of conferral.    
          Thereafter the focus of the paper will turn to health care services provision.  It will be argued 
that this is an area in which the EU only enjoys limited competences, of a “supporting and 
coordinating” nature.  The paper will examine the key principles embedded in the EU acquis and 
developed, especially by the Court of Justice of the EU, mainly in the area of the free movement of 
services; on that basis it will be argued that member states remain “sovereign” over the way in 
which they decide to design their health care systems and to regulate these activities.  
Consequently, they are fully entitled to, inter alia, restrict market access vis-à-vis non-EU providers 
and more generally to limit the reach of the market economy and of the competition rules in respect 
to health care services.  In this context, the paper will also examine the extent to which the meaning 
given to the notion of ‘undertaking’ has acted as a means of maintaining health service provision 
having a ‘mutualistic’ nature outwith free market principles.   
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            The paper will then consider the impact of the TTIP on public procurement: it will be 
reminded that this area has been significantly affected by EU legislation and is now governed by 
overarching principles of transparency and non-discrimination, in the interest of the good 
functioning of the internal market.  Nonetheless, it will also be illustrated that the existing regime 
has been applied in a far more “lenient” manner to the award of contracts in a number of sectors, all 
of which are concerned with the “essential care of the person” and whose scope includes health 
care provided by state agencies.  It will also be shown that the way in which these services are 
provided and in particular the extent to which they are placed under public control and oversight 
limits further the reach of the EU public procurement rules.  
         In its latter part the paper will address the question of whether TTIP may have any impact on 
the functioning of the National Health Service (NHS) in the United Kingdom.  It will be shows that as 
a result of the 1997 Scotland Act, which has resulted in the devolution of significant powers to the 
Scottish Parliament from the Parliament in Westminster, considerable differences have emerged in 
the way in which state-funded healthcare services are provided, respectively, in England and wales 
and in Scotland.  Whereas the latter has elected to maintain public control on the provision of these 
services ‘free at the point of need’, the former has chosen to inject progressively a number of 
market based principles in the way in which the NHS commissions the supply of these services 
South-of-the-Border.   
        Against this background, this paper will argue that since the EU lacks the competence to act in 
the field of public health beyond the limited powers conferred to it by Article 168 TFEU, it cannot 
oblige the Member States to “open up” the market for health care services to greater rivalry and in 
particular to non-EU providers.  It will be suggested that, on the one hand, the public interest goals 
of ensuring continuity of care and the demands arising from having to protect high levels of public 
health and even the survival of their populations are likely to provide the Member States with 
grounds for justifying restricting the freedom of movement of services that conform with the Treaty. 
And on the other hand, it will be illustrated that the “light touch” regime that EU public procurement 
legislation expressly allows for the award of public contracts concerning services of “essential care to 
the person” is very likely to allow awarding bodies to confine their selection of winning bids to 
undertakings chosen on the basis of “non-economic criteria”, including those inspired by 
geographical proximity.   
         In this specific respect, it will be submitted that even in a “neo-liberal” framework such as that 
provided by the 2012 Health and Social Care Act for England and Wales the notion of “patients’ 
interest” is going to allow awarding bodies to limit the reach of “value-for-money” considerations 
when it comes to identifying providers and at the same time remain compatible with competition 
law.   It will also be shown that the commitment made by the EU Commission to excluding health 
care, as part of a “package” of essential services to the individual, from the TTIP reach reflects its 
concern for respecting the principles of conferral and of subsidiarity in this “sensitive area”.  In light 
of the above, it will be concluded that the TTIP should not be regarded as a threat to public services 
and especially to the provision of health services ‘free at the point of need’, as alleged by several 
stakeholders.  It will be illustrated that the choice between “opening up” to the market or 
maintaining public control over these activities remains firmly with the Member States, each 
according to their own institutional set up. 
 
2. The EU as an international actor: of competences, powers and treaties… 
2.1. General remarks—the Treaty-making powers of the EU before the TFEU 
Since its inception, the European Economic Community, having been endowed with legal 
personality, has been able to enter into international agreements with non-Member States or 
international organisations for the purpose of furthering its objectives and in areas in which it had 
competence to act—whether exclusive or shared. 1 The original text of the EC Treaty only provided 
                                                            
1 See chiefly case 22/70, Re: ERTA, [1971] ECR 263, para. 13. 
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for a few express treaty-making powers, most notably in the field of trade with non-Member 
countries.  
        The “list” of competences, however, was not limited to those expressly enshrined in the Treaty: 
as early as in 1970s the Court of Justice of the then EEC took the view that "(...) the system of 
internal Community measures may not (...) be separated from that of external relations"2 and that 
its remit should be determined in light of the wider context of the scheme of the Treaty.3 Thus, it 
was held that external powers could also be “implied" in other Treaty provisions concerning 
“internal” competences in certain cases. 4   In this respect, it was especially essential to consider 
whether the Community had already relied on its competences in order to enact common rules 
designed to regulate a specific area.5   
          In the Court’s view, “as and when” these “internal” powers were exercised only the 
Community could exercise the authority to enter into agreements with third countries or 
international bodies that affected the application of these common rules.6 Member States, on their 
part, were de facto “pre-empted” from negotiating international obligations, either unilaterally or 
jointly, in areas in which the Community enjoyed and has already exercised powers granted to it by 
the Treaty, even though no express mention was made that these powers also entail external action 
competence.7 In the words of the Court of Justice, “(…)to the extent to which Community rules are 
promulgated for the attainment of the objectives of the Treaty, the Member States cannot, outside 
the framework of the Community institutions, assume obligations which might affect those rules or 
alter their scope. (…)”.8 
            Later judgments, however, seemed to signal a gradual retreat from such a generous view of 
the Community/Union's external competences: 9  thus, it was held that any implied authority to 
negotiate international treaties could only be advocated by the EC/EU if the corresponding internal 
power had already been deployed10 and consequently, the internal measures in issue should have 
"largely covered" the same policy area on which the proposed treaty had effect.11  While this was 
not meant to require absolute correspondence between the latter and the EC/EU measures 
concerned, it was read as requiring an assessment of the "nature and content" of the EC/EU 
provisions", of their "current state and (...) future [likely] development."12   On that basis, it was held 
that implied treaty making authority could only be justified if unilateral action on the part of the 
member states, with a view to negotiating an international agreement in a given area, was liable to 
endanger the integrity of existing internal EC/EU rules.13 
               The Court of Justice of the EU also clarified whether any implied authority to conclude 
international treaties, if it could be found, would be exclusive to the EC/EU or shared with the 
member states,14 by emphasising that this question only be addressed having regard to both the 
nature of the corresponding internal competence and to the extent to which the latter had already 
                                                            
2 Id., para. 19. 
3 Id., para. 15. 
4 Case 22/70, Re: ERTA, [1971] ECR 263. 
5 Id., para. 16. 
6 Id., para. 17. 
7 Id., para. 18. 
8 Id., para. 22.  See also e.g. Opinion 1/76, Re: Inland Waterway Vessels Convention, [1977] ECR 741.  For 
commentary, see Emiliou, "Toward a clearer demarcation line?", (1994) 19(1) ELRev 76 at 82-83; also Hartley, 
The Foundations of European Union Law, 8th Ed., 2014: OUP, pp. 180-181. 
9 Opinion 1/94, [1994] ECR I-5267. 
10 Id., para. 77; see also para. 85-86. 
11 Opinion 2/91, Re: ILO Convention No 170, [1993] ECR I-1061, para. 9-11. 
12 Opinion 1/2003, Re: Lugano Convention, [2006] ECR I-1145, para. 126-127. For comment, see Cremona, 
“Extending the reach of the AERT principle”, (2009) 34(5) ELRev 754 at 762-763. 
13 Opinion 2/91, cit. (fn. 11), para. 26. 
14 Case 22/70, cit. (fn. 4), para. 22. 
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been exercised:15 if the EC/EU had not taken any action, then, in the Court's view, the Member 
States remained jointly competent to negotiate and stipulate international agreements in this area 
in a unilateral fashion.16  Exclusive competence, instead, was reserved to cases in which the Treaty or 
a legislative act expressly recognised it or in which unilateral action on in the international plain, 
undertaken by the Member States, could have jeopardised the effectiveness of existing EU/EC 
measures.17  As to the manner in which treaty making powers should be exercised in areas of shared 
competence, the Court of Justice took the view that both the EC/EU institutions and the member 
states were subject to a duty of loyal cooperation and that, accordingly, negotiations should be 
conducted by the Union with the participation of the Member States; in addition, it was held that 
the resulting Treaty would be subjected to ratification at domestic level.18   
         In light of the forgoing analysis, it can be concluded that, largely thanks to the purposive 
interpretation adopted by the CJEU, the EC/EU has enjoyed increasingly significant treaty-making 
powers, both express and implied, in numerous areas encompassed by the Treaties: however, the 
Court has, especially of late, sought to establish more stringent criteria for the identification as well 
as the determination of the nature—whether exclusive or shared—of these unexpressed powers.  
 
2.2. The Treaty of Lisbon and the system of EU competences: implications for the Union's external 
action 
 
 The previous section endeavoured to give an overview of some basic principles governing the 
EC/EU's treaty making powers and in that context emphasised the role of the principles of conferral 
and of the doctrine of "parallelism" to determine the scope of the Union's implied external 
authority.  This section will focus on the question of whether the TFEU has had any consequences for 
the approaches identified so far.  As is well known, the Treaty of Lisbon expressly recognises that the 
Union enjoyed legal personality, in Article 47 TEU.  In addition it has resulted in a “wholesale 
reordering” of the Union’s own competences: thus, the latter are in principle shared with the 
member states unless the Treaty itself explicitly states that they must be either exclusive to the 
Union or that the Union can only act to coordinate or support or “complement” national action, 
either individual or collective.  
      Consistently with these commitments, the TFEU aimed  to “crystallise” the principles governing 
the recognition of “implied” external powers: 19 according  to Article 216(1) the EU enjoys the power 
to “conclude an agreement with one or more third countries (…) where the Treaties so provide or 
where the conclusion of an agreement is necessary in order to achieve, within the framework of the 
Union’s policies, one of the objectives referred to in the Treaty (…)”; it can also do so when 
stipulating an agreement with non-member countries is “provided for in a legally binding Union act” 
and where it is “likely to affect common rules or alter their scope”.20   
            Commentators suggested that this provision provided a legal basis for an unexpressed treaty-
making power in very limited circumstances: such is the case, for instance, if an envisaged 
international treaty affects an area already “largely covered” by Union law, having regard to the 
Union measures’ purpose, content and to the corresponding likelihood that the international 
commitments would encroach upon their integrity,21 clearly in order to maintain the coherence and 
                                                            
15 Opinion 2/91, cit. (fn. 11), para. 89-90; see also para. 104. 
16 Id., para. 105. 
17 See e.g. Commission v Luxembourg (Re: Open Skies agreement), [2002] ECR I-9741, para. 61-62 and 64-67; 
see also para. 84 and 87-88. 
18 Opinion 1/94, cit. (fn. 9), para. 107-108.  See also, inter alia, Case C-431/05, Merck Genericos, [2007] ECR I-
7001, especially para. 31-35. 
19 Kostadinides, “EU foreign policy under the doctrine  of implied powers”, (2014) 39(4) ELRev 511 at 512-513. 
20 See Opinion 1/2003, cit. (fn. 12), para. 132-133; for comment, see e.g. Hartley, The Foundations of European 
Union Law, 8th Ed., 2014: OUP, pp. 174 ff.; see especially p. 185-186. 
21 See inter alia Opinion 1/2003, cit. (fn. 12), para. 126-128; for commentary, Kostadinides, cit. (fn. 19), p. 513. 
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effectiveness of existing Union rules.22  In any other case, however, external action on the part of the 
Union could only be justified in the silence of the Treaty if it could be shown that external 
commitments were "indispensable" for internal action to be taken and given effect to: this would be 
limited to cases where, having regard to the subject matter of the relevant internal measures, the 
latter could not effectively achieve their objectives without external action being adopted in the 
same field.23  In the view of Advocate General Kokott, to hold that such implied external power could 
be exercised before adopting internal rules first would result, in the AG view, in the confines of the 
EU’s treaty-making powers becoming “virtually indeterminate”.24  
         The Treaty of Lisbon also sought to shed more light on the question of how to determine the 
nature—whether shared or exclusive—of such unexpressed treaty making powers. According to 
Article 3(2) TFEU, exclusive external competence arises not only when EU law so provides (either in 
the Treaty itself or in a legislative act)but also when "an international   agreement is “necessary” to 
enable the EU to exercise its internal powers or “insofar as its conclusion may affect common rules 
or alter their scope”.25 Commenting on this provision, it was suggested that as a result of the Treaty 
of Lisbon external powers whose existence is implied from corresponding internal powers26 would 
only be exclusive if it could be shown, on the basis of a comprehensive analysis of the nature and 
content of any internal measures already adopted in the same area, that the agreement is going to 
affect a field “already covered to a large extent” by EU rules27 and consequently, allowing the 
member states to negotiate the agreement independently undermined the full effectiveness of 
these internal EU rules.28   
          In any other area, instead, the Union and the Member States would remain jointly competence 
to act on the international plain; as a result, any agreement stipulated in these fields would be a 
"mixed" one.29  On this point, it was submitted that this is especially likely to occur in cases in which 
the Union enjoys competence to act internally which has not been exercised already in a field that 
an international agreement is going to influence30 or when any internal competence is not “pre-
emptive” in nature, e.g. if it only entails a power for the Union to enact measures laying down 
“minimum requirements”, leaving the member states free to introduce more stringent legal 
standards.31   How are these principles likely to affect the EU’s powers to negotiate and conclude 
TTIP?  It is argued that this question must be answered on the basis of a careful reading of the rules 
governing external competence.   
           There is little doubt that the Union enjoys, in matters of “international trade”, exclusive 
competence to act, in accordance with Article 3 TFEU.  Nonetheless, it is undeniable that the scope 
of the proposed agreement encompasses matters going beyond “traditional” international trade 
issues.  While the Treaty of Lisbon has altered and widened the scope of the “common commercial 
policy”,32 TTIP has been envisaged as covering matters other than those now enshrined in Article 133 
TFEU and therefore potentially falling within the shared competence of the EU and of the Member 
States.33   Consequently, it is argued that since this agreement is going to affect areas in which 
                                                            
22 Ibid. 
23 Case C-81/13, Commission v Council, Opinion of AG Kokott of 17 July 2014, nyr, para. 54-55; see also para. 
58, 70 and 74-81; para. 111-112.  See also the judgment of the Court, para. 61-62. 
24 Id., para. 126-128; see also judgment of the Court of 18 December 2014, para. 62. 
25 Per AG Kokott, para. 132-33; for commentary see e.g. Konstadinides, cit. (fn. 19), p. 524. 
26 See Konstadinides, cit. (fn. 19), p. 524. 
27 Opinion 1/03, cit. (fn. 12), para. 126-127. 
28 Id., para. 132-133; see also para. 128. 
29 See Kostandinides, cit. (fn. 19), p. 524. 
30 See inter alia, Kostadinides, cit. (fn. 19), p. 526; also, mutatis mutandis, Cremona, “Balancing Union and 
member states interests”, (2010) 35(5) ELRev 678 at 692. 
31 Kostadinides, cit. (fn. 19), p. 526; see e.g. Opinion 1/94, cit. (fn. 9), para. 103-104. 
32 Opinion 1/08, Re: GATS, [2009] ECR I-11129, para. 119-120. 
33 Mutatis mutandis, see id., para. 133-134. 
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member states retain the authority to act autonomously, TTIP is likely to be a “mixed agreement”.34   
On this point, it should be emphasised that in a letter dated 16 October 201435 and addressed to 
presidents and chairmen of parliaments and parliamentary committees of a number of member 
states the Commission seemed to suggest that the treaty would be of this nature; consequently, it 
was stated that it should be subjected to both the procedural requirements provided by the TFEU for 
the negotiation of international treaties and to the ratification processes in force in each domestic 
jurisdiction.36  
           In the EU Commission’s view, the “interplay” between these two distinct sets of safeguards 
would be able to secure that the interests of the member states be protected and in particular that 
the “input” of their parliaments be maintained: in this specific respect, it was stated  that the role of 
the Council (at the outset of the process as well as when the latter comes to its end and the 
Commission has drafted a proposal on the conclusion of the agreement, in light of the negotiations) 
and of the European Parliament which must be asked to consent to the agreement in the event of 
approval of the agreement would act as a sufficiently strong “check” on the Union’s action, in the 
spirit of openness and cooperation.37  Thus, it could be argued that in this particular case the 
features and the nature of mixed agreements are likely to provide a significant degree of protection 
for the member states’ sovereignty by ensuring their participation, albeit in accordance with the 
duty of mutual cooperation and consequently their input in negotiations concerning, among others, 
the provision of certain types of services and other economic activities having implications for the 
public interest.38   
           It is admittedly too early in the negotiations to speculate on what the “final deal” on TTIP is 
going to be and as a result, to assess, as required by the CJEU’s case law and also by the TFEU, its 
“content and purpose” in order to answer the questions on competence posed by the requirements 
contained in Articles 216(1) and 3(2).  Nonetheless, it is argued that the exercise of these powers, 
even in an area in which international action is accepted as that of common commercial policy, 
cannot take place in a vacuum but must always conform to the principle of conferral: thus, regard 
must be had  not only to the power to act on the international plain for the purpose of regulating 
trade with non-member states, but also to the question of whether such external action is likely to 
affect other policy areas in which the Union may only enjoy shared competence.39  
          Having regard in particular to TTIP, even accepting that in principle its competence is exclusive 
in matters of “common commercial policy”, specific provisions of the proposed agreement, 
especially in respect of economic activities and sectors of “public interest significance” must be 
closely scrutinised and if they fall in areas of competence that are shared with the Member States, 
negotiations must be conducted in cooperation with national governments; furthermore, the 
resulting treaty is in all likelihood going to be a “mixed” instrument and as such is therefore going to 
be ratified at domestic level.  As was forcefully held by the Court of Justice itself, it is only to the 
extent that these questions are addressed and the appropriate procedural and substantial 
requirements are fulfilled that the reciprocal limits existing, respectively, between the Member 
States and the Union’s competences can be secured.40   
             In light of the forgoing analysis, it may be concluded that the EU can only rely on its external 
competence in accordance with the overarching requirements of the principle of conferral and in 
                                                            
34 See e.g. id., para. 133-135.  See also, inter alia, Report to the House of Commons, “The Transatlantic Trade 
and Investment Partnership”, 18 December 2014, available at: www.parliament.uk/briefing-
papers/sn06688.pdf  
35 C(2014) 7557 final, available at: http://ec.europa.eu/transparency/regdoc/rep/3/2014/EN/3-2014-7557-EN-
F1-1.Pdf.  
36 Id., p. 2.  
37 Id., p. 3. 
38 See e.g., mutatis mutandis, opinion 1/08, cit. (fn. 32), para. 134. 
39 Opinion No 1/08, cit. (fn. 32), para.132. 
40 Id., para. 133, 135-136. 
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that context in the full respect of the concurring powers of the member states. Thus, the answer to 
the question of whether the Union can, by entering into TTIP, impose an obligation on its members 
to introduce reforms in, inter alia, the area of public health services’ provision can only be answered 
in light of the analysis of the more general question of whether the Union enjoys powers in this field 
and, if so, of which nature.  These issues will be addressed in the following sections. 
 
 
 
 
 
 
3. Public health care and the Single Market: a “special type” of services? 
3.1. Healthcare provision and the single market: a “special type” of services? 
 
The previous sections gave a brief account of the treaty-making powers enjoyed by the EU and 
attempted to place these powers in the wider context of the principle of conferral, which governs 
the exercise of the whole array of powers that the Member States have bestowed upon the Union.  
This section will consider the extent to which the Partnership agreement is likely to influence how 
the delivery of health care services may be provided within the Union after its stipulation in the 
Member States and especially the UK. 
           It was argued in section 2.2 that the exercise on the part of the EU of its treaty-making powers 
can legitimately occur only if it respects the principle of conferral: therefore, proposed international 
agreements must be scrutinised in their content and purpose with a view to determining whether 
such competence exists and whether all or any of their provisions may fall in fields of joint 
competence that require, therefore, the involvement of the member states in the negotiations and a 
separate ratification process in the respective jurisdictions.  On this point, it was suggested that due 
to its wide remit, TTIP was most likely to be a “mixed agreement”, since its scope was likely to 
embrace not just “classical” commercial policy issues (such as among others the lowering or the 
elimination of custom duties) but also matters concerning, inter alia, services provision and even the 
settlement of investor-state disputes.41 
        In light of the forgoing, it is now legitimate to query what the position of healthcare services is 
vis-à-vis the TTIP negotiations:  can the Union undertake international obligations affecting this 
policy area? In particular, can the Union mandate that the Member States grant “access to all areas” 
to non-EU companies when it comes to providing for the health of their citizens, as suggested by 
some stakeholders in the current debate?  It is suggested that regard should be had to the existence 
and scope of any competence—whether internal or external—that the EU may claim in this field and 
especially to the extent to which the principles governing the single market and the rules on 
competition apply to the provision of health services on the part of domestic health authorities.  In 
particular, it has been queried whether they can be regarded as an “economic activity” for the 
purpose of applying the free movement rules.  It was further asked whether the manner in which 
individual EU nationals access these services in a different member state can affect their enjoyment 
of the right to move freely across the internal market and, if that is indeed the case, what is the 
scope of the power of a member state to, e.g. place conditions on that access and, more generally, 
lay down rules governing their cross-border provisions without infringing the Treaty rules. 
        According to consistent case law of the CJEU it is now established that health care services 
constitute “services” within the meaning of Article 56 TFEU:  in SPUC v Grogan ruling, the Court 
made clear that in so far as a “(…) medical activity which is normally provided for remuneration (…) 
[is] carried out as part of a professional activity (…)” would be covered by the scope of the Treaty.42  
As a result, “(…) persons receiving medical treatment (…) are to be regarded as recipients of 
                                                            
41 Id., para. 136. 
42 Case 159/90, SPUC v Grogan, [1991] ECR I-4685, para. 18. 
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services”;43 thus, the exercise on their part of the freedom to seek medical treatment that is publicly 
funded should not be unduly hampered by rules governing, for instance, the public funding of these 
services either in their own country or in the state where treatment is sought: as was forcefully 
stated in the Kohll judgment, while in the absence of harmonisation individual member states are 
allowed to set out rules governing the entitlement to healthcare benefits, these rules cannot 
contravene the requirements of the free movement of services.44  In the CJEU’s view, the “special 
nature” of certain types of economic activity can “(…) not remove them from the ambit of the 
fundamental principle of freedom of movement (…)”.45   
           As a result, it was held that “(…) the Treaty precludes the application of any national rules 
which have the effect of making the provision of services between Member States more difficult 
than the provision of services purely within one Member State (…)”.46 Unless it could be shown that 
these domestic rules were "objectively justified" in light of "(...) an overriding reason of public 
interest",47 such as the concern for safeguarding a "balanced and open medical and hospital service 
open to all (...)"48  Member States could not place conditions or limitations on the freedom of their 
nationals to obtain medical services elsewhere in the Union that made the exercise of their rights 
under the Treaty excessively difficult.49  
          Thus, it was held in inter alia, the Gearets-Smits decision that Member States could establish 
rules designed to govern the reimbursement of medical expenses for services obtained by the 
patient in a different member state with a view to securing "(...) treatment capacity or medical 
competence on national territory” and, as a result, the attainment of high levels of public health in 
each member states that are necessary to guarantee the survival of the population.50  Nonetheless, 
any such arrangement was only allowed within the limits enshrined in Article 56 TFEU: the Court 
took the view that since the rules governing access to cross-border medical services and in particular 
the reimbursement of expenses could discourage individuals from seeking medical care elsewhere in 
the internal market,51 they could only be justified if its rules were appropriate to attaining goals of 
"sufficient and permanent access to a range of high quality [medical] treatment” and to “prevent (…) 
any wastage of financial, technical and human resources”52 they were also “(…) based on objective, 
non-discriminatory criteria which are known in advance, in such a way as to circumscribe the 
exercise of the national authorities' discretion, so that it is not used arbitrarily (…)”.53 
           In light of the forgoing analysis, it is submitted that Member States do not only remain 
“sovereign” in determining how to design and regulate their healthcare systems. They can also rely 
on Article 52(1) TFEU in order to introduce those restrictions on the right to freedom of movement 
of services that are regarded as being both "necessary" and "proportionate" for the attainment of 
such public interest goals such as preserving the accessibility of these "sensitive services" 
throughout the Union as well as protecting the financial stability of the authorities and bodies 
providing them.  To this end, it is however indispensable to ensure that these national arrangements 
are both suitable for the attainment of an “overriding reason in the public interest” and conform 
with principles of predictability, non-discrimination and of certainty, as well as being applied in a 
non-arbitrary fashion. 
                                                            
43 Cases 286/82 and 26/83, Luisi and Carbone v Ministero del Tesoro, [1984] ECR 377, para. 16. 
44 Case C-156/98, Kohll, [1998] ECR I-1931, para. 17-18. 
45 Id., para. 20. 
46 Id., para. 33. 
47 Id., para. 36 and 41. 
48 Case C-158/99, Geraets Smit, [2001] ECR I-5473, para. 82. 
49 Id., para. 72. 
50 Id., para. 73-74. 
51 Id., para. 75. 
52 Id., para. 77-79. 
53 Id., para. 90; see also para. 87-89. 
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          It is added that how member states, in the exercise of their “sovereign powers” over their 
national healthcare systems, decide to design the latter can have a considerable impact on other 
single market principles such as the applicability of certain rules on competition.  As is well known, 
one of the essential preconditions for the application of Articles 101 and 102 TFEU is that the entity 
prima facie responsible for allegedly anti-competitive behaviour be an “undertaking” i.e. a unit 
which, regardless of its legal status or the way in which it is financed, performs an economic activity, 
that is an activity involving the supply of goods or the provision of services in exchange for the 
payment of a price.54  In Fenin the General Court drew a distinction between the performance of 
these activities for and according to purely solidarity-based principles and for the purpose of 
drawing a profit:55 on that basis, it took the view that in so far as national health authorities, for 
instance, purchased large supplies of, e.g., medical equipment to be used to provide “universal” 
healthcare benefits to individuals, financed via social security contributions and supplied free-of-
charge, they would not be acting as “undertakings” for competition law purposes.56  
         In the Court’s view, while it was accepted that in these circumstances the health authorities 
were able to exert significant influence on the behaviour of their suppliers, their supply-side activity 
could not be separated from the fulfilment of their statutory mandate, for which these purchases 
were conducted.57  It followed that since the provision of services to citizens was not of an 
“economic” nature, but rather, was based on principles of universality and of solidarity, the 
institution or body engaged in such purchasing practices, which, arguably, could in appropriate 
circumstances constitute the expression of the exercise of monopsony power, could not be subject 
to the application of the Treaty competition rules.58 
            In light of the forgoing analysis, it may be concluded that healthcare services fall within the 
scope of the Founding Treaties and are therefore subject to the principles enshrined therein: 
although the CJEU has acknowledged their importance for the public interest they nonetheless 
represent “services” for the purpose of both Article 56 TFEU and, to the extent that they are 
supplied as part of an “economic activity”, also of Articles 101 and 102 TFEU.  However, it is equally 
clear that member states enjoy extensive powers when it comes to designing and regulating the 
framework for their provision: in that context, they can choose to “take healthcare out of the market 
outright”, by providing these services to all individuals, free of charge and in accordance with 
principles of solidarity and universality.  Furthermore they can lay down conditions and 
requirements that individuals affiliated to other EU countries must comply with in order to access 
health care services in their own territory; nonetheless, the exercise of this power is in any event 
confined and disciplined by the principles of “necessity” and “proportionality” and in that context if 
domestic authorities are recognised any discretion as to the application of these rules, the exercise 
of these powers must conform to canons of predictability, non-discrimination and non-arbitrariness.  
The next section will examine the other question of the extent to which the EU can act in the field of 
healthcare services and for that purpose will consider both the nature of the competence enjoyed by 
the Union and how this interacts with the “sovereignty” that member states retain vis-à-vis their 
healthcare services. 
 
3.2. Healthcare services and the TFEU—between limited competences and the good 
functioning of the single market… 
 
The previous section considered the question of the “nature” of state-funded health services in the 
context of the TFEU and argued that while these services remain subject to free movement and (in 
so far as they may be provided as part of an “economic activity”) competition principles, member 
                                                            
54 See inter alia joined cases C-264/01 and others, AOK Bundesverband and others, [2004] ECR I-2493, para. 46. 
55 Case T-319/99, FENIN v Commission, [2003], ECR II-357, para. 35, 38. 
56 Id., para. 36-37; see also para. 39-40. 
57 Id., para. 36. 
58 Id., para. 39; see also case C-205/03 P, Fenin v Commission, [2006] ECR I-6295, para. 25-27. 
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states retain a relatively significant power of appreciation in determining the way in which they 
should be provided, especially in “cross border” situations, albeit within the limits enshrined in 
Articles 49 and 56 of the Treaty.   
             But what are the implications of this approach for the EU’s own powers? In other words, can 
the Union adopt measures affecting the provision of healthcare services, including those that are 
publicly funded?  According to Article 6 of the TFEU, public health is included among those areas of 
competence in which the Union enjoys limited powers of action, being allowed only to take 
measures designed to “support, coordinate and supplement” the action already adopted by the 
Member States.  According to Article 168(7) TFEU the Union can only take action to complement 
domestic measures and policies, with a view to, inter alia, encouraging mutual coordination and in 
that context improving the “complementarity of their health services in cross border areas (…)”, for 
the purpose of ensuring a high level of human health protection.59  
          Importantly, the last subsection of the same provision, consistently with the case law on free 
movement discussed in section 3.1, expressly states that the member states can therefore decide 
independently how to organise, design and finance healthcare provision within the respective 
jurisdictions.60  The EU institutions, on their part, can only enact measures to encourage state 
coordination in, inter alia, the provision of health care services in cross-border situations so as to 
ensure that the sovereign powers enjoyed by the member states in this area do not unduly encroach 
upon the free movement of persons and of services’ rules.61  On this point, it is suggested that a 
good example of how this power is to be exercised is provided by the “Patients’ Directive”, i.e. 
Directive 2011/24/EU, laying down “(…)rules for facilitating access to safe and high-quality cross-
border healthcare in the Union (…),[ensuring] patient mobility (…) and to promote cooperation on 
healthcare between Member States (…)”.62  For this purpose, the Directive crystallises63 a number of 
rights that the CJEU had already been recognised for EU citizens enjoying their free movement rights 
vis-à-vis health authorities, including, for instance, the entitlement to the reimbursement of 
expenses incurred in seeking cross-border health services that are among the benefits to which they 
would have been entitled in their state of origin64 and, after the provision of such services, to obtain 
any “follow-up” assistance in their home country that would have been offered to them had they 
been treated in their own country.65   
              Thus, it is argued that in this area the “supporting competence” of the Union has been 
exercised in order to ensure that the functioning of the single market is not unduly impaired in the 
face of the significant autonomy enjoyed by the member states in respect of healthcare matters, 
especially by avoiding that the good functioning single market is unduly impaired as a result of state 
measures governing the provision of healthcare services according to the needs of their own 
populations.66  In this context, it must also be emphasised that the choice of the extent to which 
these services are exposed to free market principles is for the member states to determine, in 
accordance with the principle of subsidiarity.67   
           In light of the forgoing analysis, it is submitted that the answer to the question of whether the 
stipulation of TTIP could result in the EU member states being obliged to "open up" their health care 
                                                            
59 See e.g. , mutatis mutandis, case C158/96, Kohll, [1998] ECR I-1931, para. 18. 
60 See e.g. case C372/04, Watts, [2006] ECR I-4325, para. 86 and 92; see also case C-385/99, Muller-Faure’, 
[2003] ECR I-270, para. 102-103. 
61 See e.g. C-157/99, Geraets-Smits et al., [2001] ECR I-5473, para. 44-45. 
62 Directive of the European Parliament and the Council of 9 March 2011No 24 on the application of patients’ 
rights in cross-border healthcare, [2011] OJ L88/45, Preamble, Recital 10. 
63 Id., recital 11. 
64 See Article 7 of Directive 2011/24. 
65 See Article 5(c).  
66 See e.g. Sauter, “The impact of EU Competition law on national healthcare services”, (2013) 28(4) ELRev 457 
at 463-465. 
67 Ibid.; see also, mutatis mutandis, Opinion 1/08, cit. (fn. 32), para. 133, 136; also case C-385/99, Muller-
Faure’, [2003] ECR I-270, para. 102-103; Fenin, cit. (fn. 55), para. 38-40. 
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services' markets to greater competition, especially from non-EU based firms,68  appears to be 
largely negative.  As was illustrated earlier although common commercial policy matters fall within 
the scope of the Union's exclusive competence, the latter can only be exercised within the scope of 
the principle of conferral.69  It was illustrated earlier that health care provision is a field in which the 
EU only enjoys "coordinating" and "supporting" competence, that is the power only to ensure that 
the "sovereignty" maintained by the member states over publicly funded health care provision does 
not distort the functioning of the internal market.  Member States, on their part, whilst remaining 
relatively autonomous in disciplining access to these services, can only introduce those domestic 
arrangements that are appropriate to the pursuit of the public interest to, e.g. the stability of their 
health systems and proportionate to the objective they seek to achieve.70  Subject to these limits, 
they can therefore choose, for instance, to keep the provision of these services under state control 
and ownership or to limit the involvement of the private sector to a minimum; they can also 
introduce rules designed to regimenting access to these markets on the part of firms that are based 
outwith their territory if this is demonstrated to be both proportionate and necessary to the pursuit 
of goals of, e.g., continuity of care.71 
           Against this background, it is argued that the Union could not, via TTIP or indeed any other 
international trade instrument, oblige the member states to adopt a certain “model” for the 
provision of health care services or indeed to alter their choices as to whether to limit the space for 
the free movement of these services on the basis of public interest considerations, so long as they 
do not unduly interfere with the functioning of the internal market and especially with the smooth 
circulation of services. In this respect, it is suggested that it appears unlikely that the Union could 
advocate an unexpressed power to act on the international plain even by means of treaties 
concerning policy matters in respect of which it enjoys exclusive competence: it is submitted that 
measures such as the "patients Directive", far from seeking to harmonise the rules concerning the 
provision of these services, are carefully limited to smoothing out any national differences that may 
affect the functioning of the single market.  As such, these powers would not therefore meet the 
requirements laid out by Articles 216 and 3(2) TFEU for the purpose of grounding "derived treaty 
making powers"72 on the ground that the internal competence could effectively be exercised 
without the need to adopt external measures concerning, e.g., the treatment of third country 
nationals.73  
            In light of the forgoing, it is argued that the Union lacks the treaty-making powers that are 
required to enter into obligations with third countries affecting the area of health care, given the 
limited scope of the internal powers it enjoys in this field: it is suggested that since its competence 
under Article 168 TFEU is limited to ensuring the efficient circulation of services in cross border 
situation within the internal market and does not therefore affect the treatment of third country 
nationals,74 its exercise in the form of internal measure does not require the EU to negotiate 
agreements with third countries.75  Accordingly, it is argued that unless the member states were 
prepared to negotiate an amendment in the TFEU to confer on the EU more pervasive powers of 
regulation and harmonisation in this area, the Union could not, via the medium of TTIP or in other 
ways, mandate the member states to adopt a certain type of institutional framework for the 
                                                            
68 Opinion 1/76, Re: Inland Waterway Vessels Convention, [1977] ECR 741. 
69 See also, e.g., Opinion 1/2003, Re: Lugano Convention, [2006] ECR I-1145, para. 126-128; see also para. 133. 
70 See inter alia case C-157/99, Geraets-Smits et al., [2001] ECR I-5473, para. 44-45; also case C-372/04, Watts, 
[2006] ECR I-4325, para. 86. 
71 See e.g. , mutatis mutandis, case C158/96, Kohll, [1998] ECR I-1931, para. 18. 
72See inter alia Opinion 1/03, cit. (fn. 12), para. 126-127; see also case C-81/13, cit. (fn 23), para. 57-59; see 
also AG Opinion, para. 102-104 and 106-107. 
73 Id., para. 106-107. 
74 See mutatis mutandis, id., para. 64-65; see also para. 78-80. 
75 Id., mutatis mutandis, para. 69-70; see also judgment of the Court of 18 December 2014, para. 44-46 and 52-
55. 
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provision of publicly funded healthcare services that would allow, inter alia, for the extension of the 
free movement of services’ rules to providers established in a third country.   
          On this point, it also appears unsurprising that according to a recent statement, the 
Commission has committed itself to keeping health care services outside the realm of the TTIP 
negotiations.76  The memorandum published in July 2014 by DG Trade,77 confirms that the 
partnership deal would preserve the power of EU Governments to limit the reach of the principle of 
“national treatment” and “market access” to healthcare provision, including the possibility of 
opening up health care markets to competition78 and of reducing the scope for third country 
individuals and firms to enter and operate within the single market.79  
           This commitment was also reiterated in communications occurring directly with the United 
Kingdom Parliament: in a letter dated 8 July 2014 and addressed to the Chair of the All-Party 
Parliamentary Group on TTIP, the Director for the USA and Canada division of the EU Commission’s 
Directorate General for Trade. In the letter, Mr Garcia Bercero expressed the view that adhering to 
TTIP would not affect the “rights of the Member States to manage their own health systems 
according to their various needs”.80  To quote verbatim from the letter, “the EU does not intend to 
change its approach to health services in trade negotiations for TTIP”; consequently, Member States 
remain entitled to, inter alia, establish rules deigned to “control access to their health services 
markets by foreign suppliers, without constraints under EU trade agreements.”81   
           It is added that this position would likely not be affected by considerations concerning the 
nature of TTIP: as was also observed by DG Trade this treaty, despite being negotiated under the 
wide remit of the common commercial policy, i.e. an exclusive competence, is in all probability going 
to be a mixed agreement, in view of its remit and of the demands of the principle of conferral.  It is 
acknowledged that this type of instrument is capable of allowing the Member States to "defend 
their sensitive interests".82  However, it is argued that the implications stemming from the nature of 
the agreement itself do not address the more general questions as to the allocation of powers of the 
Union vis-a-vis the Member States, which therefore remain the main obstacle vis-à-vis any action on 
the part of the Union affecting this area.83 Thus, it is submitted that the partnership deal, even if 
concluded as a mixed agreement, could not go as far as to oblige domestic governments to reform 
their health systems so as, inter alia, inject "more market" into their functioning, on the ground that 
just as the EU does not enjoy sufficiently extensive internal powers in this area, it also lack the 
corresponding external authority to achieve these objectives. 84  
           It may be concluded that the principle of conferral precludes the EU from introducing 
measures resulting or encouraging the "privatisation by stealth" of national health care framework 
either via internal action or through the stipulation of international trade treaties.  As was illustrated 
so far, the limited powers enjoyed by the Union in respect of health care matters would not, save for 
an amendment to Article 168 TFEU, allow it through TTIP to restrict the sovereignty that Member 
                                                            
76 See: http://trade.ec.europa.eu/doclib/press/index.cfm?id=918. A text of the draft mandate was leaked  in 
March 2013 to the “Inside US Trade” website; it was marked with the reference: COM(2013) 136 final; see 
also, mutatis mutandis, Article 14, General Agreement on Trade in Services, available via: 
http://www.wto.org/english/docs_e/legal_e/26-gats_01_e.htm#articleXIV; see also draft mandate, cit. (fn. 
39), Annex, para. 6 and 14. 
77 See: http://trade.ec.europa.eu/doclib/press/index.cfm?id=1115.  
78 Ibid. 
79 Ibid. 
80 See the letter sent to John Healey MP (Chair, All Party Parliamentary Group on TTIP) by Ignacio Garcia-
Bercero, DG Trade, EU Commission, on 8 July 2014, available at: 
http://trade.ec.europa.eu/doclib/docs/2014/july/tradoc_152665.pdf.  
81 Ibid. 
82 Opinion 1/08, cit. (fn. 32), para. 136. 
83 Id., para. 127. 
84 Ibid.; see also para. 128 and 132; see also para. 136. 
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States maintain over their publicly funded health systems and in particular to push them toward 
"market oriented models" when designing or reforming the relevant institutional frameworks.    
 
3.3. “Contracting out” healthcare services in Europe: does TTIP de fact offer a “backdoor in” 
for third country providers?  
 
The previous section discussed the nature of the competence enjoyed by the EU in the field of 
healthcare and showed that in accordance with Article 168 TFEU the Union can only act with a view 
to "supporting and coordinating" domestic action in this area and in particular to prevent the 
application of these domestic rules form fettering the functioning of the single market in cross 
border cases, with the Member States being  fully "sovereign" over the provision of publicly funded 
health services.85   
         It is however beyond doubt that private enterprise play a role (which is in some instances 
significant) in the delivery of these services, through the stipulation of contracts with the competent 
public authorities.  The purpose of this section is therefore to address the question of whether TTIP 
is likely to increase the accessibility of public procurement markets for non-EU companies.  As is well 
known, EU legislation has been introduced with a view to harmonising the principles and also the 
procedures according to which contracts whose monetary value is above a certain set of thresholds 
are assigned by public authorities:86 at the core of these measures are a commitment to 
transparency and non-discrimination (especially on grounds of nationality) of potential contractors, 
so that equality of opportunity to secure these contracts is respected and the functioning of the 
single market is not adversely affected by making it more difficult from firms established in other 
member states to bid for selection.87   
           Having regard in particular to non-EU firms, the current legislation expressly states that the 
Union is committed to guaranteeing to these would-be bidders conditions that are no less 
favourable than those enshrined in the WTO’s Government Procurement Agreement, that is, the 
international law instrument negotiated and concluded within the framework of the World Trade 
Organisation with a view to ensuring the reciprocal opening up of the markets for public works and 
services to firms located in the territories of the Organisation’s members.  But, in view of the 
“sensitive” nature of healthcare services and of the correspondingly limited scope of the powers 
enjoyed by the EU in this field, to what extent can this commitment to mutual access to the 
respective markets be upheld? 
           The debate concerning the negotiations of TTIP has indicated since the very start that this is a 
“hard fought” field:88 according to the EU Commission’s Mandate, obtaining greater access to US 
public procurement, at least at Federal level, represented a key objective of the Union’s negotiating 
position.89  Several European stakeholders, on the other hand, claimed that if non-national or non-
EU providers were allowed to bid for these contracts in conditions of non-discrimination, this would 
have resulted in public services (including health care) becoming more exposed to free market 
principles and in quality standards being lowered.90  Having regard more specifically to the 
functioning of the NHS in the United Kingdom, it was claimed that the stipulation of TTIP could have 
                                                            
85 Case C-372/04, cit. (fn. 70), para. 105. 
86 See chiefly Directive of the European Parliament and the Council 2004/18/EC, [2004] OJ L134/114. 
87 Id., see e.g. Preamble, Recitals 1-3. 
88 See e.g. House of Lords Select Committee on the EU, Sub-committee C, 14th Report, “The Transatlantic Trade 
and investment partnership agreement”, session 2013-14, available at: 
http://www.publications.parliament.uk/pa/ld201314/ldselect/ldeucom/179/179.pdf, para. 131; see also EU 
Commission, Communications of 14 June 2013, available at: 
http://trade.ec.europa.eu/doclib/press/index.cfm?id=918.  
89 See e.g. State of Play of negotiations after 6th Round, July 2014, available at: 
http://trade.ec.europa.eu/doclib/docs/2014/july/tradoc_152699.pdf, p. 2. 
90 See e.g. John Hillary, “On TTIP and the NHS, they’re trying to bamboozle us”, 14 July 2014, available at:  
https://www.opendemocracy.net/ournhs/john-hilary/on-ttip-and-nhs-they-are-trying-to-bamboozle-us.  
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potentially wide-ranging and so far unclear consequences, due to the increasing push on the part of 
the Westminster Government especially to introduce "market based" principles in this sector,91 to 
which, it was often suggested, TTIP would contribute.92   
              While, as will be illustrated later, these concerns have been felt especially in England and 
Wales93 and less in Scotland where these services have excluded from the remit of free market 
principles,94  questions remain as to the extent to which foreign and especially non-EU based firms 
may still bid for public contracts concerning healthcare provision both North- and South-of-the-
Border.95  In this respect, it may be queried whether Member States' health authorities can in some 
way limit access to the relevant bidding procedures on the basis of, e.g. geographical criteria 
associated with the localisation of service providers and aimed at pursuing non-economic goals such 
as, inter alia, maintaining continuity and quality of care for patients.96 
         As a preliminary point, it must be noted that the current Directive concerning the award of 
public contracts appears to be consistent with the same principles underpinning Article 168 TFEU, 
namely that, in application of the principle of subsidiarity, “essential services to the person” and in 
particular health care falls within the power of the member states to decide how to organise their 
provision:97 thus, its Preamble expressly acknowledges that the provision of these services takes 
place, within each member state, in a “(…)particular context that varies widely amongst Member 
States, due to different cultural traditions (…)”.98  Accordingly, domestic authorities retain significant 
discretion as to the manner in which these services should be supplied and in that context can “(…) 
organise the choice of the service providers in the way they consider most appropriate (…)”.99   
            National agencies responsible for the provision of publicly funded health care services can 
therefore opt for doing so "in-house", that is either directly or via entities that they themselves 
control; 100  they can also decide to grant licenses to outside bodies that meet objective selection 
criteria identified in advance.101  Alternatively, health authorities can decide to "contract out" 
specific services and select the firm or firms to which the relevant contracts should be awarded on 
the basis of criteria that are not solely based on the "value-for-money" principle  but also on more 
quality-based requirements,102 such as, inter alia, a concern for ensuring the “continuity in the 
provision of public services” or for allowing organisations based on solidarity-led governance 
principles (such as, inter alia, workers’ cooperatives or other organisations in which service users 
participate in the provision of the services) to bid for relevant contracts.103  
          In light of the forgoing, it is argued that albeit within the constraints placed on their powers by 
principles of transparency and non-discrimination underpinning the award of any public contract, 
member States enjoy a power of appreciation in deciding whether to grant access to these 
procedure and in particular can opt for limiting the scope of application of criteria that are purely 
                                                            
91 See inter alia Curran and Albert, “It seemed a good idea at the time”, (2014) 35(9) ECLR 419; see also 
Pownall, “Neoliberalism, austerity and the Health and Social Care Act 2012”, (2013) 42(4) Industrial L J 422 at 
429-430. 
92 See e.g.: http://www.patients4nhs.org.uk/eu-us-free-trade-agreement-or-ttip/.  
93 Ibid. 
94 See e.g. SPICe Briefing, “The National Health Service in Scotland”, 21 June 2011, No 11/49, pp. 5-6. 
95 Ibid. 
96  See Directive of the European Parliament and the Council No 2014/24/EU, [2014] OJ L94/65, Preamble, 
Recital 118. 
97 See inter alia, mutatis mutandis, case C-300/07, H &C Oymanns GbR and others, [2009] ECR I-4779, para.51-
56; see also para. 59. 
98 Directive of the European Parliament and the Council No 2014/24/EU, [2014] OJ L94/65, Preamble, Recital 
114. 
99 Ibid. 
100 See e.g. case C-324/98, Telaustria, [2000] ECR I10745, para. 60-61. 
101 Ibid., fn. 142.  See also Directive 2004/18/EC, OJ 2004 L134/114, Annex II B. 
102 Ibid.; Inter alia, see case C-321/03, Coname, ECR I-7287, para. 16-19. 
103 Id., fn. 142, Recital 118, Preamble. 
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economic in nature, such as those based on "value-for-money" in the selection of winning bids.104  
EU legislation, on its part, recognises and upholds the application of a "light touch regime" to 
healthcare as part of these sensitive services to the person and thus allows to the bodies responsible 
for the award of these contracts significant discretion in governing their provision.105 
            Against this background it is suggested that applicability of the EU public procurement 
legislation can be severely restricted in its application to these activities.   Thus, in Teckal the Court 
of Justice took the view that when a Member State opted for the "in-house" supply of these services, 
either directly or via controlled entities, the public procurement rules would not apply beyond the 
general principles of transparency and non-discrimination mentioned above.106  In Commission v 
Ireland it was added that contracting authorities would not be obliged to “go out to tender” if 
services were entrusted with another public body and performed as part of their statutory duties.107 
More generally, the Court has recognised in several judgments that so long as they conform to 
principles of legal certainty and transparency and are not applied in an arbitrary or discriminatory 
fashion, the awarding bodies can identify and apply selection criteria that are not of a purely 
“economic” (i.e. value or price-based) nature even when, due to the manner in which services are 
provided, "going out to tender" is the only solution.108  
        It is added that similar considerations would also likely allow the member states to regiment, in 
the context of the “light touch regime” described above, to exclude from public procurement 
procedures specific categories of undertakings, including those who are affiliated to third countries, 
on the ground that they would not satisfy requirements based on the need to ensure continuity and 
accessibility in public service provision that, in turn, may entail, inter alia, geographical proximity 
between their suppliers and those who benefit from them.109  Having regard in particular to 
providers based outside the EU, it is acknowledged that as a result of the General Procurement 
Agreement, WTO members are under an obligation to respect the principle of non-discrimination 
and consequently must not make the entry into their public procurement markets for firms affiliated 
to fellow member states "unduly burdensome".  Nonetheless, it should be emphasised that 
according to its Annex IV,110 “social and health services” are expressly excluded from the principle of 
equal treatment, thus allowing signatory states to restrict access to the market for the provision of 
these services to foreign suppliers if that is regarded as necessary to maintain high levels of health 
protection within their territories.111   
      Having regard more specifically to trade deals involving the Union, a similar approach seems also 
to have emerged in the negotiations of the recent Trade Agreement concluded with Canada (CETA): 
its Annex II expressly states that the terms of the deal will not apply to certain “sensitive” types of 
public services, among which healthcare features prominently.112  Thus, it is argued that publicly 
funded healthcare services are in all likelihood going to be excluded from the remit of any trade 
                                                            
104 See e.g. Wiggens, “Public procurement rules and cooperation between public sector entities”, (2011) 5 
PPLR 157, especially pp. 158-159. 
105 See Directive of the European Parliament and the Council No 2014/24/EU, [2014] OJ L94/65, Preamble, 
Recital 118. For commentary, mutatis mutandis, inter alia, Brown, “Seeing through transparency”, (2007) 1 
PPLR 1, especially pp. 19-21. 
106 Case C-107/98, Teckal Srl, [1999] ECR I-8121, para. 49-51. 
107 Case C-532/03, Commission v Ireland, [2007] ECR I-801, para. 26-28; see also para. 35-36. 
108 See e.g. most recently, case C-568/13, Azienda Ospedaliero-Universitaria di Careggi-Firenze v Data Medical 
Service Srl, judgment of 18 December 2014, nyr, para. 32-35; see also, inter alia, case C-305/08, COniSMA, 
[2009] ECR I-12129, para. 37, 43. 
109 See e.g., mutatis mutandis, case C-160/08, Commission v Germany, judgment of 29 April 2010, para. 124 ff. 
110 WTO, General Procurement Agreement, Appendices and Annexes, available at: 
http://www.wto.org/english/tratop_e/gproc_e/appendices_e.htm#ec.  
111 See e.g., in respect of pharmaceutical trade, Acquah, “Extending the limits of protection of pharmaceutical 
patents and data outside the EU”, (2014) 45(3) IIC 256 at 268-269. 
112 See CETA—summary of the final negotiations, available at: 
http://trade.ec.europa.eu/doclib/docs/2014/december/tradoc_152982.pdf, pp. 10-11. 
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liberalisation deal involving the EU, including TTIP.   This outcome appears particularly probable in 
light of the position expressed by the EU Commission in a recent letter.    Writing to members of the 
UK Parliament, the erstwhile Director for Trade with responsibility for “Neighbouring countries—
USA and Canada” expressed the view that the EU was not planning to change its position in this 
area; it was confirmed that EU member states retain “full policy space” in this field, and 
consequently remain competent to regiment—even to the point of negating it altogether—entry 
and participation within the market for healthcare services (including those that are publicly funded) 
for non-European providers.113   The EU for its part could only be bound by its obligations under the 
current WTO regime according to which, as illustrated earlier, these services would remain excluded 
from the remit of the principle of equal treatment.114 
          In light of the forgoing analysis, it may be concluded that while TTIP is likely to facilitate 
reciprocal access for EU and US based businesses in their respective procurement markets generally, 
it is not going to alter the “light touch nature” of the regime governing the award of contracts in the 
field of healthcare provision or of the supply of other “sensitive” services.    But what about member 
states who have already decide to “inject free market principles” into healthcare provision? Is this 
domestic choice likely to alter this conclusion? The next sections will consider the framework for the 
provision of healthcare services respectively in Scotland and in England and Wales, with a view to 
assessing whether the obligations that TTIP is expected to involve are likely to facilitate the 
“internationalisation” of healthcare services’ provision and of public procurement when domestic 
legislation has already introduced a degree of “privatisation” in this area. 
 
4. Healthcare services in the United Kingdom and the impact of the single market and of the 
common commercial policy at EU level: a tale of two nations? 
 
4.1. The NHS in Scotland: relying on cooperation and state “control” and “ownership” as a 
means of seeking optimal provision of care 
 
The previous sections analysed the scope of the competence enjoyed by the EU in the field of 
healthcare services and highlighted the very narrow contours designed for it by Article 168 TFEU and 
argued that unless the member states decided to amend the Treaty so as to confer on it more 
generous ability to take action, the Union would not be able to mandate, through an international 
instrument, any greater access of these markets to third-country providers than the one that 
domestic legislation and regulation currently allows in each jurisdiction.   
          It is however undeniable that, just as they retain the power to regiment entry into these 
economic areas vis-à-vis non-EU providers, member states can choose to adopt a “market oriented” 
approach to their provision, that may well involve allowing foreign providers into normally 
“national”, if not local, markets.  It is submitted that a good example of the potentially divergent 
solutions that can be adopted to address this issue is the one offered by the National Health Service 
(NHS) in the United Kingdom: as is well known, the aim of the NHS is to provide medical care 
financed by the taxpayer “free at the point of need” to individuals resident within the UK.  The 
Service enjoys high level of citizens’ trust and represents a key “cost component” in the British 
budget: according to data originating within the British Treasury, NHS costs in the years 2010/11 
accounted for £121 bn or 8.2% of the country’s total GDP.115  In the years 2013/14 this figure was 
                                                            
113 See the letter sent to John Healey MP (Chair, All Party Parliamentary Group on TTIP) by Ignacio Garcia-
Bercero, DG Trade, EU Commission, on 8 July 2014, available at: 
http://trade.ec.europa.eu/doclib/docs/2014/july/tradoc_152665.pdf.  
114 Supra, this section, fn. 110 and 111 and accompanying text. 
115 See e.g. House of Commons, Note: NHS funding and expenditure, SN/SG/724, 3 April 2012, available at: 
http://www.nhshistory.net/parlymoney.pdf, sect. 1.1-1.2. 
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approximating £114 bn—slightly lower, but still extremely significant and to date the highest single 
item of expenditure per function within the whole UK budget.116  
       Its structure has, however, been the target of significant reforms in the past 20 years, in 
response to concerns for its efficiency and financial sustainability.  Demands for greater devolution 
of powers from the Westminster Parliament to the assemblies representing the population of the 
UK’s nations and especially of Scotland have also been influential in this process which has resulted 
in the “Scottish arm” of the Service adopting a very different structure than the one characterising 
the NHS in England and Wales.  The purpose of this section will be to provide a short overview of the 
NHS in Scotland and thereafter to attempt to gauge, however briefly, the extent to which the 
framework for healthcare provision in force North-of-the-Border is likely to be affected by the 
implementation of common commercial policy objectives affecting these services on the part of the 
EU.   
         As was anticipated, the power to legislate on the structure and functioning of the NHS in 
Scotland has represented a “devolved matter” to the Parliament in Holyrood since the 1997 Scotland 
Act: the Scottish Parliament has expressly maintained the NHS “in public hands”.117  Today, its 
running is devolved by the Government to a structure of fourteen area boards, responsible for the 
allocation of resources and the implementation of healthcare strategies via NHS Boards, Community 
Health Partnerships and Operating Divisions.118  These bodies operate according to principles of 
cooperation and are under direct control of the competent Minister.119  Performance objectives are 
set by the Scottish Government: NHS Boards are fully responsible for the implementation of the 
delivery plans that they sign with Government, by which they are also monitored and supported in 
the course of their activities.120  
           Under the leadership of the Government’s General Directorate for Health, the Boards, acting 
as “all-purpose organisations”, provide services to patients either directly or by commissioning them 
to independent contractors, such as, among others, GPs, dentists and pharmacies.121  Hospital care is 
provided under direct control of the Boards, organised on a territorial basis.  NHS Boards also work 
in close cooperation with local authorities and communities, via local area partnerships.   Overall 
quality of service and assurance of continuity of provision are guaranteed via specialised agencies, 
such as Healthcare Improvement Scotland.122  At the core of the Scottish NHS’s strategy is a 
commitment to providing “(…) safe, high quality services that are as local as possible and as 
specialised as necessary”.123  This objective is met in a variety of ways, ranging from the provision of 
services “in –house”—either directly or via bodies under the control of the NHS Scotland’s Boards—
or through the commissioning of these services in accordance with framework agreements that are 
negotiated on a UK wide basis.124   
             Central to this activity is a strong emphasis on collaboration, partnership and the sharing of 
resources across the sector; in addition, the fact that there is often no “split” between purchaser 
and provider means that there is no such a thing as a “contract” for the supply of key services: this is 
the case for hospital care, which is managed “in-house” by a bespoke operating division within each 
Board.125  Consequently, it is suggested that since these practices can be regarded as forms of 
                                                            
116 See e.g. the summary data available at: http://www.nhsconfed.org/resources/key-statistics-on-the-nhs.  
117 See e.g. SPICe Briefing, “The National Health Service in Scotland”, 21 June 2011, No 11/49, pp. 5-6. 
118 Ibid. 
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121 Ibid. 
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123 See Kerr Report: Delivering for health, 2 November 2005, available at: 
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internal organisation within a "unitary structure", they are very likely to fall outside the scope of 
competition law scrutiny, just as any other form of "single firm conduct".126 
        In light of the above it is argued that the choice of the Scottish Parliament has been very much 
in the sense of leaving publicly funded healthcare largely out of the market and under governmental 
control, by limiting the input of private providers in the provision of healthcare services, by 
maintaining key activities, such as the provision of hospital care, within NHS Boards and by managing 
significant areas of primary care, including GP services, under the strict supervision of local 
partnerships.127  It is submitted that the emphasis on keeping taxpayer-funded healthcare under 
direct rule from Government may be regarded as instrumental to the attainment of non-economic 
goals such as continuity and accessibility of care and of overall stability (financial and institutional) of 
the overall NHS North-of-the-Border128 and thus remains consistent with Article 168 TFEU. 129  
           It is argued that the choice of keeping the Scottish NHS "in public hands" has important 
consequences for the applicability of the EU rules on competition and on the free movement of 
services.130  On this point, it is submitted that due the Scottish Government strong commitment to 
principles of universality and solidarity in the provision of publicly funded healthcare, the latter is 
unlikely to constitute an "economic activity" in the meaning conferred to this concept by the Court 
of Justice in, inter alia, the FENIN decision.  Consequently, it is argued that arrangements aimed at 
ensuring cooperation and resource-sharing among different health boards and agencies within as 
well as outwith the Scottish NHS may escape the application of the Union competition principles.131 
            Having regard more specifically to the provision of services to patients, it is added that since 
these activities appear to be carried out mainly either "in-house" or via controlled entities, the 
contracts concluded for this purpose are very likely to be immune from the application of the "bulk" 
of the EU Public Procurement legislation.132  And finally, the circumstance that in any other case the 
award of these contracts, being concerned with "essential services to the person", is subject to a 
"light touch regime" under the relevant Union legislation is going to allow those Boards that may 
have to opt for "going out to tender" to regulate the access to the bidding process and to select the 
winning offers on the basis of criteria that are non-economic and thus not strictly based on the 
value-for-money principles: as was discussed above, this "lighter regime" would permit domestic 
agencies to subordinate their decision to the fulfilment of requirements based on other factors, such 
as geographic proximity or the extent to which the bidders may be non-profit organisations in which 
service users may also be involved.133    
          It is concluded that the concerns that the Partnership agreement could affect the status quo 
characterising the functioning of the NHS in Scotland appear unjustified: not only does Article 168 
TFEU protect the "sovereignty" of the Scottish Government and Parliament over regulation of and 
access to their taxpayer-funded health systems, albeit within the limits enshrined in the TFEU.  The 
Scottish administration remains also entitled to rely on non-economic criteria in designing and 
regimenting the framework for the publicly funded provision of these services when the latter are 
supplied by private entities, thanks to the “light-touch regime” provided by the Public procurement 
legislation in this area.   
 
4.2. State-funded healthcare in England and Wales—toward a “neoliberal” framework for 
the provision of these services… but what does this mean for market access? 
                                                            
126 See e.g., mutatis mutandis, case C-73/95, Viho Europe v Commission, [1996] ECR I-465. 
127 Id., see e.g. pp. 5-6 and 17-18. 
128 See e.g. case C372/04, Watts, [2006] ECR I-4325, para. 86 and 92; see also case C-385/99, Muller-Faure’, 
[2003] ECR I-270, para. 102-103. 
129 Ibid.; see especially pp. 18-19. 
130 See e.g. C-157/99, Geraets-Smits et al., [2001] ECR I-5473, para. 44-45. 
131 Case T-319/99, FENIN v Commission, [2003], ECR II-357, para. 35-40. 
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The previous section briefly outlined the key principles governing the design and the functioning of 
the NHS in Scotland and in that context discussed the impact of these choices, which are strongly in 
the sense of maintaining this sector of the healthcare industry in Government's hands, on the 
applicability of the free movement of services and competition rules contained in the TFEU, as well 
as their implications for the continuing observance of the obligations enshrined in the current EU 
Public Procurement legislation. 
           The situation is, however, admittedly very different in England and Wales: as anticipated, 
whereas the Scottish Government, especially in the years between 1999 and 2007, “back-tracked” 
from a sustained move aimed at opening up these services to the free market forces, the solutions 
adopted by the Coalition Government in office since 2010 have aimed at resuscitating many of the 
ideas behind the objective of creating a “internal market” of health care services.  The Health and 
Social Care Act 2012 was enacted for the purpose of “(…)promot[ing] competition amongst an 
increasingly diverse base of private, public and non-profit providers of public services, with the 
ultimate aim of raising the standards of service-provision and reducing its costs (…)”.134  
           To achieve these objectives, the Act abolished bodies such as the Primary Care Trusts and the 
strategic health authorities, along with the NHS executive, and replaced the former with Clinical 
Commissioning Groups (CCGs) and with a new NHS England commissioning board: CCGs are led by 
GPs and are responsible for the purchasing of medical services from third party providers, which in 
turn can either be publicly (e.g. NHS Foundation Trusts) or privately owned.135  They act under the 
supervision of the commissioning board, which is also responsible for the direct purchasing of 
certain specialised services.136   Thus, it is apparent that thanks to the 2012 Act the framework for 
the provision of healthcare services has gone back to relying on the “purchaser-provider” split and 
also to conforming to the idea of an “internal market” in services.137  Importantly, the 2012 Act 
states that NHS commissioners must not engage in anti-competitive behaviour unless restrictive 
practices are justified “in the patients’ interest”.138   
            To ensure the effective application of this principle, the Act has conferred to a sector 
regulator, Monitor, competition enforcement powers to be exercised in regime of concurrency with 
the Competition and Markets Authority (CMA).139      Monitor is also responsible for authorising new 
entities wishing to start providing healthcare services and for regulating their activity.  Having regard 
more specifically to its competition mandate, its role encompasses not only detecting and 
sanctioning anti-competitive behaviour but also the application of the competition rules in a way 
that contributes to the "patients' interests (...) by improving the quality of these services (...) and 
reducing inequalities in respect of both access to service and outcome of treatment.140  It was 
suggested therefore that this aspect of Monitor's mandate allows it to authorise otherwise 
objectionable behaviour on the ground that the latter is regarded as justified and indispensable to 
secure “(…) seamless, well-coordinated and uninterrupted provision of health care services(…)” in 
accordance with clinical considerations.141  These decisions should be inspired by qualitative, 
clinically led considerations and should focus on striking an appropriate balance between the “costs” 
associated with a loss of competition (e.g. in terms of reduced incentives to innovate or to provide 
better “value-for-money” services for providers) and the benefits accruing to patients as a result of 
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the practice: if the latter, on the whole, overcome the former, then the practice, albeit prima facie 
anti-competitive, will be deemed to be “in the interests of patients”.142   
             The 2012 Act allows commissioners to exercise a widely discretionary power when it comes 
to identifying ways in which health services may be purchased.  Nonetheless, when they “contract 
out” these activities, they are under a general obligation not to resort to procurement practices 
resulting in the “narrowing” of competition.143  In addition, and consistently with the relevant 
legislation on Public procurement, they can “(…) take into account the need to ensure [inter alia] 
quality, continuity, accessibility, affordability, availability and comprehensiveness of the services, the 
specific needs of different categories of users, including disadvantaged and vulnerable groups (…)”144 
and therefore, in accordance with general principles of transparency and non-discrimination, remain 
entitled to establish and apply selection criteria for bids that are not exclusively economic in 
nature.145 However, the application of these criteria must lead to outcomes that are at least 
“competition neutral”: in other words, any “reduction of potential competition for the contract 
[must be] clearly and soundly justified from the perspective of the clinical/medical needs to be 
satisfied” and no less restrictive alternative should have been available to the awarding body, 
especially in terms of allowing access to the process to all the potentially suitable candidate firms.146  
               The above analysis suggests that the 2012 reforms have introduced a framework for the 
publicly funded provision of healthcare services inspired by “neoliberal”, relatively market-driven 
principles.  However, in recognition of the "sensitive nature" of these services, the Act allows for 
inroads to be carved in the principle of "internal market for health services" if these restrictions are 
necessary in the patients' interest.  In addition, and consistently with the "light touch regime" 
applied to the award of contracts for essential services to the person, non-economic criteria, based, 
for instance, on quality and accessibility of services can be relied upon in selecting successful bids.   
          Having regard more specifically to the "patients' interest" clause Guidance recently published 
by Monitor states that this justification is likely to apply to prima facie restrictive practices—i.e. to 
practices that “reduce the incentives on providers to provide high-quality services, provide value for 
money and/or improve services”—which nonetheless lead to (or are likely to do so) “improvements 
in quality through cooperation in the delivery of care” or in efficiency gains that result in better value 
for money, e.g. through the reduction of “duplication” in the supply of these services.147  These 
benefits must be “material” to the practice, likely to be realised within a relatively short time and 
supported by appropriate scientific research; in addition, commissioning bodies should consider 
whether a “less restrictive alternative” exists, with a view to achieving these outcomes, vis-à-vis the 
arrangement in question.148  
              The framework for assessment proposed in the Guidance can be usefully compared with the 
approach on which the EU Commission relies in its Guidance on Article 101(3); in a similar vein as the 
one adopted by Monitor, the Guidance states that those efficiency gains that stem from “technical 
and economic progress” will be regarded as relevant for the purpose of the application of the legal 
exception of Article 101(3).149  They must be “objective”—that is, measurable and achievable—as 
well as linked by a nexus of causality to the practice.150  While in principle “cost efficiencies” that can 
be readily quantified are ostensibly the “preferred type” of benefits,151 the Commission openly 
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accepts that “qualitative efficiencies (…) may be of equal or even greater importance” than cost 
reductions and can therefore justify the applicability of the legal exception.152  In this context, 
benefits such as “technological advances” or the supply of products or services that are better suited 
to the needs of their users may fall within the broad scope of Article 101(3)(a) TFEU.153   
          As to the “negative” conditions, i.e. that the restraint be ‘necessary’ and not entail the 
elimination of competition from a substantial part of the relevant market, the Commission insists on 
the absence of a less restrictive alternative154 as well as on proof that as a result of the agreement 
the “magnitude of the remaining sources of actual competition”155 and of the threat if entry are not 
weakened to the point of allowing the parties to, e.g. impose sustained price increases.156   
         This approach can be contrasted once again with the one adopted by Monitor: according to the 
Guidance, conduct that results in benefits being attained more quickly and cost-effectively than 
would have been the case without it and that does not, e.g., discourage new competitors from 
entering the market or expanding their share is likely to be in the patients’ interests, if the positive 
conditions just outlined are also fulfilled.157 In light of the forgoing it can therefore be argued that, 
providing that the criteria set out in the Monitor Guidance are applied in a non-discriminatory and 
transparent manner, practices that, while being prima facie anti-competitive, are adjudged to be in 
the patients’ interests are not likely to be objectionable also under the generally applicable 
competition rules.158 
            It should be noted, however, that as a result of the 2012 Act, the scope of involvement of 
commercial firms in the provision of healthcare has become potentially more considerable, thus 
calling into question the extent to which the “solidarity-based” nature of their activities can exempt 
them from the application of Article 101 TFEU, as posited in, inter alia, the FENIN judgment.159  It is 
argued that the principle laid down by the CJEU in that decision is going to be applicable only if the 
act of “purchasing” these services is aimed at the later supply of healthcare free at the point of 
need.160  It is undoubted that if both purchaser and supply act in a largely solidarity-led fashion, 
FENIN would provide them with a “defence” against any accusation of anti-competitive behaviour.161  
What is uncertain, however, is whether the same outcome can be attained if one of the parties 
seeks to make a profit from healthcare provision, as may well be the case when private undertakings 
are involved.   
          In this specific respect, it was suggested that the solidarity-led, as opposed to profit-making, 
nature of the services should be taken into account not on its own, but as just one of the features of 
each case: for instance, Sauter argued that factors including the degree of control exercised on the 
providers of these services and on the services themselves by the State would be just as relevant.162 
In other words, an assessment of the activity from a “functional standpoint”, as opposed to looking 
at each contract in a “granular fashion” should be carried out in order to answer the question of 
whether, in light of FENIN, a specific arrangement concerning healthcare provision and involving 
private providers may be falling within the scope of Article 101 TFEU.163  In this context, a 
consideration of the ratio between the price charged to health authorities and the costs borne by 
the provider, of the manner in which these charges are determined and of how and by whom (i.e. 
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whether these decisions are taken by the state authorities or are left to the parties’ freedom to 
contract, for instance) the corresponding benefits for users of the services in issue are decided 
would be especially important.164         
          It may therefore be suggested that the Health and Social Care Act has heralded numerous and 
very significant changes in the way in which state-funded health care is provided in England and 
Wales: while the “citizen-facing” aspects of these important public services remain unaltered, the 
Act has opened up this sector to greater private firms’ involvement and thus paved the way to a 
degree of rivalry and to wider market access.  However, as was illustrated above, this does not 
appear likely to lead to the full “marketization” of the NHS: it is argued that if, as a result of a careful 
analysis of the modes of provision of these services, it is clear that they retain a “solidarity-based” 
nature, even when they are supplied via a non-state actor, the rules on competition may not be 
applicable to the activities undertaken by the entities concerned. 165  It is added that, as was shown 
having regard to the role and approach adopted by Monitor in these matters, the notion of ‘patients’ 
interest’ is likely to prove an effective instrument to introduce considerations of “public policy” in 
the assessment of prima face anti-competitive conduct (such as, inter alia, cooperation 
arrangements), so as to promote objectives of continuity of care and, more generally, to ensure 
better, more integrated care provision.166 
                It is argued that this approach is going to be unaffected in the event of the conclusion of 
TTIP.  As was illustrated in respect to the position in Scotland, the Founding Treaties allow member 
states to rely on non-economic criteria, albeit subject to principles of non-discrimination, of 
necessity and of proportionality, in order to, inter alia, restrict the possibility for non-domestic, 
including non-EU, firms to access the single market in medical services:  in this context, it could be 
argued that the very concept of ‘patients’ interest’ represents the “shortcut” for the solution which 
the Westminster Parliament has chosen to adopt for this purpose, in accordance with the principle 
of subsidiarity enshrined in Article 168(7) TFEU.   
               It should be added that broadly similar principles are relevant when it comes to considering 
to what extent undertakings established outside the Union can be allowed to bid for contracts with 
commissioning bodies, in accordance with the public procurement rules: on this point, the Guidance 
published by Monitor identifies three goals for commissioning bodies seeking to procure services, 
namely “securing the needs of healthcare service users, improving the quality of services” and 
increasing their efficiency at the point of provision.167 These objectives must be attained on the basis 
of a careful assessment of the healthcare needs existing in a certain area and also among each 
segment of the population affected.168  In doing so, these bodies must act in a transparent, non-
discriminatory and proportionate way and must seek to procure services from the entity that is 
“most capable” of securing the overarching procurement objectives while offering ‘best value for 
money’.169  To achieve these general objectives, commissioning bodies have a vast array of choices 
among the various procurement tools and procedures: Monitor takes the view that resorting to the 
publication of a contract notice is only one option open to them and that other alternatives can also 
be considered as equally appropriate in light of the framework of objectives outlined above and in 
the respect of criteria of transparency, non-discrimination and proportionality.170   
          In particular, the Guidance once again emphasises that the ultimate objective of any such 
decision must be to secure “the needs of people who use the services and improve [their] quality 
and efficiency” to which other, more economic-based concerns can and in appropriate cases should 
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be subordinate.171 Consequently, Monitor accepts that putting certain services “out to tender” may 
not always be the best option for commissioning bodies and that other, less competition-oriented 
options can be better suited to meeting these objectives:172 this may be the case, inter alia, when 
the commissioning body finds that for specific services there is only a “single capable provider”, on 
the ground that, for instance, that provider owns infrastructure that is essential to provide the 
service or when two or more services must be “co-located”, i.e. supplied in the same place for 
reasons of safety or to meet a clinical need.173     Furthermore, in selecting the “best contractor”, 
they must consider “appropriate ways of improving services”, among the options of either allowing 
coordination and integration among providers or encouraging competition and patient choice.174   
            Against this background, it is argued that when dealing with commissioning practices as well 
as with the public procurement of health services, commissioning bodies can, for instance, rely on 
criteria that are not economic in nature, such as, inter alia, those dependent on the geographic 
location of the provider vis-à-vis the territory for which the commissioning body is responsible, in 
order to identify suitable bidders, provided that general requirements of transparency, 
proportionality and non-discrimination are met.175 So long as they act fairly and transparently, the 
awarding agencies can therefore subject the selection of both the most appropriate procurement 
framework and of criteria of selection for suppliers that are not solely tied to the concept of “best 
value for money”.176 Consequently, it is suggested that the Guidance remains broadly consistent 
with the “light touch approach” that guides the application of the EU relevant legislation in the 
context of “essential services to the person”.177   
          In light of the forgoing analysis, it may be concluded that the organisation of the NHS in 
England and Wales could not be made to morph into a “market-driven” framework through an 
international agreement stipulated jointly by the EU and the member states.  As was illustrated so 
far, the parliament in Westminster remains the ultimate “custodian” of the NHS in those geographic 
areas in which it enjoys competence to legislate: in this context it remains entitled to rely on the 
“exceptions” to principles of competition law and to the single market rules that the Founding 
Treaties provide in order to restrict the reach of “possible providers” only to those, for instance, 
based in the EU or even in smaller, more local areas.  Furthermore, commissioning bodies retain 
significant discretion when it comes to deciding whether services should be “put out to tender” and 
also to setting criteria for the selection of suitable bidders, albeit within the general framework of 
principles governing public procurement at Union level.   
 
5. Tentative conclusions: TTIP and publicly funded health care in the United Kingdom—access 
(almost) denied? 
 
The Transatlantic Trade and Investment Partnership represents a very promising but at the same 
time challenging trade deal, involving two among the largest world’s economies: it is undeniable that 
by reducing trade barriers in key economic areas the agreement is likely to lead to export increases 
from Union member states into the US and vice versa, thus encouraging economic growth.  At the 
same time however, the significant differences existing between the two economic and legal 
systems are going to bring new challenges for policy makers at Union and at domestic level.  This is 
especially clear in respect of public services’ provision and especially of healthcare services.  Against 
this background, it is therefore not surprising that the debate has been so polarised, with many 
stakeholders, especially belonging to civil society, greatly concerned that TTIP could be used as some 
                                                            
171 Id., p. 38-39. 
172 Id., p. 39. 
173 Id., p. 41. 
174 Id., p. 26. 
175 See e.g. id., p. 28. 
176 Id., pp. 45 ff. 
177 See e.g., mutatis mutandis, recital 114 of the Preamble to the Directive 2014/24, cit. (fn. 98). 
24 
 
form of “back door” for the “privatisation by stealth” of public services generally and healthcare 
specifically. 
          It is however clear from the forgoing analysis that this danger is more imagined than real: as 
was illustrated in section 2, the Union, in accordance with the principle of conferral, can only act in 
those policy areas in which it enjoys authority under the Treaty and can only do so to the exclusion 
of the Member States when the Treaty expressly provides it with sole competence.  By contrast, all 
other policy areas are regarded as either shared with the member states or in several cases are only 
limited to the power to “support” domestic action, especially when the latter can affect “cross-
border” situations.  Thus, it was argued that even though the legal basis for the negotiation of TTIP 
can be found in Article 133, i.e. in the area of common commercial policy, which is exclusive in 
nature, the exercise of powers in this field cannot occur without ignoring the constraints that, due to 
the significant remit of the agreement, the framework of competences established by the Treaty 
imposes on the EU.   
            On that basis, it was therefore suggested that, first of all, to the extent that the envisaged 
deal affected areas in which competences remained shared, the agreement could only be concluded 
in conjunction with the member states, that is, in the form of a “mixed agreement” and after having 
allowed the national governments to represent their legitimate interests in the course of the 
negotiations.  And second, the Union could not, via TTIP, alter the nature and order of the powers 
that the member states themselves had conferred upon it, by for instance mandating  the member 
states to “open up to the market” their healthcare services, due to the limited powers enjoyed by 
the Union in this area, according to Article 168 TFEU. 
            On that basis, it was argued that neither TTIP nor any other international instrument is likely 
to threaten the power to design, regulate and finance health care services via the NHS in the way 
that is seen as “appropriate to the needs of [the] population” either in Scotland or in England and 
Wales.  Article 168 TFEU is in fact going to preserve the UK nations’ “sovereignty” over health 
services without allowing the Union to instigate their “marketization.  Thus, it was submitted that 
just as domestic authorities are allowed to carve exceptions, based on objective justifications in the 
public interest and within the constraints of the Treaty, into the principle of free movement of 
services, they remain competent to regiment access to their healthcare service markets to firms 
established in third countries.  Similarly, it may be suggested that the light touch regime affecting 
the award of such contracts would entail scope for selection criteria to be based on “geographic 
proximity” of providers to users of services.     
          It is acknowledged that the 2012 reforms of the National Health Service in England and Wales 
have been very controversial and have resulted in gulf emerging between the nations North and 
South-of-the-Border.  However, it is argued that since the Westminster and Holyrood parliaments 
remain “sovereign” over decisions in the area of healthcare, the stipulation of TTIP will not lead to 
any dramatic change in the status quo.  As was shown in section 4, significant and effective checks 
are in place to allow for the scope of application of the competition and public procurement rules to 
be limited, if not altogether excluded.  In this respect, it was suggested that the ‘patients’ interest’ 
exception enshrined in the Health and Social Care Act for England and Wales and the strong state 
control on healthcare provision which characterises the NHS in Scotland are likely to provide legal 
justifications for the limitation of the right to free movement of services and of equal treatment of 
foreign providers that remain in line with the Treaty’s own principles.  Thus, it was argued that the 
stipulation of TTIP would not be capable of altering this position on the ground of the Union’s 
acknowledged lack of authority in this area and also in light of the widely held concern, which is 
manifested, inter alia, in the WTO acquis as well as, more recently, in the recently concluded 
Canada/EU trade arrangement CETA, that these activities should be maintained outside the remit of 
the principle of equal treatment for non-national firms. 
           In light of the forgoing analysis, it is concluded that while the proposed trade deal remains 
controversial for a number of reasons, ranging from the lack of transparency of the negotiations to 
the concerns arising from its proposed rules on investor-state dispute settlement, its scope is highly 
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unlikely to encompass much cherished public services such as healthcare, save for the Member 
States agreeing to a treaty amendment affecting the current dictum of Article 168 and thereafter 
accepting key changes in their own legal and institutional systems. The principles of conferral and 
subsidiarity represent key safeguards for the integrity of European tradition in public service 
delivery, which cannot change unless the member states as masters of the EU Treaties decide to do 
so.  In this context, domestic governments can choose to open up healthcare and other “sensitive” 
services to competition; however, the EU cannot be held responsible if this indeed occurs.  
 
